Physician profile
Avi Das
NPI 1073990057
$4,983.25
in general payments reported to CMS, 2019-2025
21 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $675 · 2021: $1,179 · 2022: $589 · 2023: $321 · 2024: $600 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $871.69 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $626.81 | 2019-2023 | |
| Pfizer INC. | $626.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $529.65 | 2019-2025 | Fasenra, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $293.98 | 2019-2022 | |
| Abbvie INC. | $276.06 | 2021-2024 | Avycaz, Teflaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.11 | 2019-2021 | |
| Gilead Sciences, INC. | $246.74 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.08 | 2019-2025 | Jardiance |
| Inari Medical, INC. | $188.60 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Otsuka America Pharmaceutical, INC. | $176.59 | 2019 | |
| Mylan Specialty L.P. | $161.36 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $92.77 | 2022-2024 | Dificid |
| Portola Pharmaceuticals, LLC | $90.99 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $58.94 | 2019-2025 | Ozempic, Rybelsus |
| Csl Behring | $42.09 | 2019-2023 | Kcentra |
| Cmp Pharma, INC. | $33.12 | 2021 | |
| Alexion Pharmaceuticals, INC. | $28.22 | 2021 | |
| Janssen Biotech, INC. | $20.32 | 2024 | Rybrevant |
| Paratek Pharmaceuticals, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avi Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.